Hemispherx: FDA decision on Ampligen won't come until fall

07/23/2009 | American City Business Journals

The FDA might take until fall to decide on Hemispherx BioPharma's application for Ampligen, an experimental treatment for chronic fatigue syndrome, because of staffing problems, said Dr. William Carter, the company's president and CEO. The biotech firm, which Carter said has been communicating with the FDA since May, is in discussions with potential marketing partners while the agency reviews the product.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ